en · de · es · fr · pt
semax-notes.peptides5388.com › News › Semax Peptide Structure And Origin — Explained

Semax Peptide Structure And Origin — Explained

By Editorial Desk · published 2025-08-31 · last reviewed 2025-09-15 · News

This is a working overview of intranasal route, written for readers who want more than a one-paragraph summary but less than a textbook.

This page was last updated on 2025-09-15 and is reviewed periodically as new material appears.

Semax Peptide Structure and Origin

Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its design combines the ACTH(4-7) core fragment with a C-terminal Pro-Gly-Pro extension, a modification intended to improve stability and prolong activity. The molecule is hydrophilic, carries no lipid chains or glycosylation, and has a theoretical mass just over 810 daltons in its free form. All seven residues are proteinogenic amino acids, so no non-natural building blocks appear in the backbone. A free N-terminal methionine and C-terminal proline define the unmodified parent peptide.

The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.

Background and Development

Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.

Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.

Semax at a glance

PropertyValueNotes
Chemical classSynthetic heptapeptideACTH(4-7) analogue
SequenceMet-Glu-His-Phe-Pro-Gly-ProFree N terminus, unmodified side chains
Molecular weight813.9 DaFree base; salt forms differ
AppearanceWhite to off-white powderLyophilised solid
SolubilityFreely soluble in waterHydrophilic; polar solvents preferred

Semax Peptide Background and Identity

Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.

Semax is a synthetic seven-amino-acid peptide whose sequence extends the ACTH(4-10) fragment with a C-terminal proline-glycine-proline tripeptide. The commonly cited sequence is Met-Glu-His-Phe-Pro-Gly-Pro, giving a molecular formula near C37H51N9O10S and a molecular weight close to 813.9 g/mol. It belongs to the broader class of synthetic ACTH fragments studied for central nervous system effects rather than for adrenal steroid stimulation. In practice the material appears as a lyophilized white powder for laboratory work or as a dilute saline solution in clinical settings.

Related pages on this site

Semax Background and Chemistry

The compound is registered in Russia as a pharmaceutical product, most commonly formulated as a nasal solution, and has been used in that setting since the 1990s. Outside that jurisdiction it is generally handled as a research chemical rather than an approved medicine. Regulatory status therefore differs sharply between countries, and material sold internationally may not correspond to the Russian pharmaceutical formulation. Documentation with commercial samples is typically limited to a certificate of analysis covering purity and identity, not clinical status or local legal classification.

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It corresponds to the ACTH(4-7) fragment extended at the C-terminus by a Pro-Gly-Pro tripeptide, an addition intended to slow enzymatic breakdown. The molecular formula is C37H51N9O10S and the molecular mass is approximately 814 daltons. In the literature it is often described as an ACTH(4-10) analog, although that label reflects a naming convention as much as a precise structural relationship. The compound was developed in Russia and remains most closely associated with that research tradition.

Reference notes

== Pharmacokinetics == Many drugs follow the multi-compartment model. In other words, a drug may have a preference for a particular body compartment which will result in the majority of that drug to ultimately settle in that particular compartment. For highly polar drugs very little will be in the tissues of the body For highly lipophilic drugs majority of drug will be located in body tissues Initially, because the drug is given intravenously, the drug will distribute to the central compartment (i.e. circulation system). The drug (e.g. lipophilic drug) will move out of the central compartment and move into the peripheral compartments The movement from one compartment to another is influenced by passive diffusion (Moves from an area of high concentration to one with low concentration) A drug like fentanyl is very fat soluble. Initial doses ‘wear off’ relatively quickly because the drug redistributes to adipose tissue. However, if the infusion is ongoing then the peripheral compartment (body tissue) will have a large store of fentanyl The duration of infusion determines whether or not steady state was reached Once a drug enters the body, elimination and distribution begins. Initially the drug present in central compartment (i.e. circulation system) is being distributed into the tissues, and being eliminated At steady state, the concentration of free drug in the central compartment (i.e. circulation system) is equal to the concentration of free drug in the peripheral compartment (i.e.

== Genes == There are two major forms of the GNRHR, each encoded by a separate gene (GNRHR and GNRHR2). Alternative splicing of the GNRHR gene, GNRHR, results in multiple transcript variants encoding different isoforms. More than 18 transcription initiation sites in the 5' region and multiple polyA signals in the 3' region have been identified for GNRHR.

== UPSC Museum == The Museum Building is located within the premises of the UPSC, the Dholpur House, Shahjahan Road, New Delhi. There prevailed for a long time a feeling that an institution like the Union Public Service Commission that has in its possession a rich treasure of archival material: original Pamphlets, Documents, reports, and other Records not easily accessible to the public, should have a Museum providing the public a window to have a vision of the great journey of this august institution. Accordingly, the Union Public Service Commission decided to set up a A museum where such materials could be aesthetically displayed for discerning visitors.

Intrahepatic cholestasis of pregnancy (ICP) is an acute cause of cholestasis that manifests most commonly in the third trimester of pregnancy. It affects 0.5–1.5% of pregnancies in Europe and the US and up to 28% in women of Mapuche ethnicity in Chile. ICP is characterized by severe pruritus and elevated serum levels of bile acids as well as transaminases and alkaline phosphatase. These signs and symptoms resolve on their own shortly after delivery, though they may reappear in subsequent pregnancies for 45–70% of women. In the treatment of ICP, current evidence suggests ursodeoxycholic acid (UDCA), a minor secondary bile acid in humans, is the most effective drug for reducing pruritus and improving liver function. The etiology of ICP is multifactorial and likely involves hormonal, genetic, and environmental factors. Several observations suggest estrogen plays a major role: ICP begins in the third trimester, when estrogen levels are highest, resolves after estrogen levels return to normal post-delivery, and occurs with higher incidence in multiple pregnancies, where estrogen levels are more elevated than usual. Although estrogen's exact pathomechanism in ICP remains unclear, several explanations have been offered. Estrogen may induce a decrease in the fluidity of the hepatic sinusoidal membrane, leading to a decrease in the activity of basolateral Na+/K+-ATPase. A weaker Na+ gradient results in diminished sodium-dependent uptake of bile acids from venous blood into hepatocytes by the sodium/bile acid cotransporter.

Sources: en.wikipedia.org

Reference notes

The dermis is the underlying connective tissue layer that supports the epidermis. It is composed of dense irregular connective tissue and areolar connective tissue such as a collagen with elastin arranged in a diffusely bundled and woven pattern. The dermis has two layers: the papillary dermis and the reticular layer. The papillary layer is the superficial layer that forms finger-like projections into the epidermis (dermal papillae), and consists of highly vascularized, loose connective tissue. The reticular layer is the deep layer of the dermis and consists of the dense irregular connective tissue. These layers serve to give elasticity to the integument, allowing stretching and conferring flexibility, while also resisting distortions, wrinkling, and sagging. The dermal layer provides a site for the endings of blood vessels and nerves. Many chromatophores are also stored in this layer, as are the bases of integumental structures such as hair, feathers, and glands.

Stainless steel remains a piping material of choice for the pharmaceutical industry. Due to its metallic contribution, most steel was removed from microelectronics UPW systems in the 1980s and replaced with high performance polymers of polyvinylidene fluoride (PVDF), perfluoroalkoxy (PFA), ethylene chlorotrifluoroethylene (ECTFE) and polytetrafluoroethylene (PTFE) in the US and Europe. In Asia, polyvinyl chloride (PVC), chlorinated polyvinyl chloride (CPVC) and polypropylene (PP) are popular, along with the high performance polymers.

Another notable evolutionary event of the Jurassic was the appearance of true birds, descended from maniraptoran coelurosaurians. By the Early Cretaceous and the ongoing breakup of Pangaea, dinosaurs were becoming strongly differentiated by landmass. The earliest part of this time saw the spread of ankylosaurians, iguanodontians, and brachiosaurids through Europe, North America, and northern Africa. These were later supplemented or replaced in Africa by large spinosaurid and carcharodontosaurid theropods, and rebbachisaurid and titanosaurian sauropods, also found in South America. In Asia, maniraptoran coelurosaurians like dromaeosaurids, troodontids, and oviraptorosaurians became the common theropods, and ankylosaurids and early ceratopsians like Psittacosaurus became important herbivores. Meanwhile, Australia was home to a fauna of basal ankylosaurians, titanosaurian sauropods and large and small Elasmarian ornithopods. The stegosaurians appear to have gone extinct at some point in the late Early Cretaceous or early Late Cretaceous. A major change in the Early Cretaceous, which would be amplified in the Late Cretaceous, was the evolution of flowering plants. At the same time, several groups of dinosaurian herbivores evolved more sophisticated ways to orally process food. Ceratopsians developed a method of slicing with teeth stacked on each other in batteries, and iguanodontians refined a method of grinding with dental batteries, taken to its extreme in hadrosaurids. Some sauropods also evolved tooth batteries, best exemplified by the rebbachisaurid Nigersaurus.

== Separation techniques combined with mass spectrometry == An important enhancement to the mass resolving and mass determining capabilities of mass spectrometry is using it in tandem with chromatographic and other separation techniques.

=== In-orbit activities === At the start of the third orbit, Cooper checked his list of 11 experiments that were on his schedule. His first task was to eject a six-inch (152 mm) diameter sphere, equipped with xenon strobe lights, from the nose of the spacecraft. This experiment was designed to test his ability to spot and track a flashing beacon in orbit. At T+3 hours 25 minutes, Cooper flipped the switch and heard and felt the beacon detach from the spacecraft. He tried to see the flashing light in the approaching dusk and on the nightside pass, but failed to do so. On the fourth orbit, he did spot the beacon and saw it pulsing. Cooper reported to Scott Carpenter on Kauai, Hawaii, "I was with the little rascal all night." He also spotted the beacon on his fifth and sixth orbits. Also on the sixth orbit, at about T+9 hours, Cooper set up cameras, adjusted the spacecraft attitude and set switches to deploy a tethered balloon from the nose of the spacecraft. It was a 30-inch (762 mm) PET film balloon painted fluorescent orange, inflated with nitrogen and attached to a 100-foot (30 m) nylon line from the antenna canister. A strain gauge in the antenna canister would measure differences in atmospheric drag between the 100-mile (160 km) perigee and the 160-mile (260 km) apogee. Cooper tried several times to eject the balloon, but it failed to eject. Cooper passed Schirra's orbital record on the seventh orbit while he was engaged in radiation experiments. After 10 hours, the Zanzibar tracking station informed Cooper the flight was a go for 17 orbits.

Sources: en.wikipedia.org

Frequently asked questions

What is Semax chemically?

It is a synthetic seven-amino-acid peptide built from the ACTH(4-7) sequence plus a Pro-Gly-Pro tail. It belongs to the family of short ACTH fragments studied for nervous-system effects. Its backbone contains only standard amino acids.

How does it relate to ACTH?

It contains the 4-7 fragment of adrenocorticotropic hormone extended at the C terminus. That truncation removes the region associated with steroidogenic activity. The design intent was to keep neurotrophic properties while avoiding full hormonal effects.

Does it occur naturally?

No natural source of the intact heptapeptide is known. It is produced by solid-phase peptide synthesis. Some related ACTH fragments arise as hormone processing products, but the Pro-Gly-Pro extension is a designed addition rather than a natural sequence.

Where was Semax developed?

It originated at the Institute of Molecular Genetics in Moscow during the 1980s. The work was carried out by a Russian research group that specialized in peptide neuropharmacology.

Network